Curi Bio Secures $10M Series B to Scale Human-Relevant Preclinical Platforms and Advanced Data Analysis for Drug Discovery
Financing led by DreamCIS will accelerate and expand development of the company’s industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data analysis to de-risk and accelerate therapeutic development. SEATTLE–(BUSINESS WIRE)–Curi Bio, a…
